These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 11281851

  • 1. Current therapies and emerging targets for the treatment of diabetes.
    Wagman AS, Nuss JM.
    Curr Pharm Des; 2001 Apr; 7(6):417-50. PubMed ID: 11281851
    [Abstract] [Full Text] [Related]

  • 2. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
    Bastarrachea RA, Montero JC, Saavedra-Gajardo I, Cerda-Flores R, Machado-Domínguez A, Comuzzie AG.
    Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
    [Abstract] [Full Text] [Related]

  • 3. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications.
    Bullock WH, Magnuson SR, Choi S, Gunn DE, Rudolph J.
    Curr Top Med Chem; 2002 Sep; 2(9):915-38. PubMed ID: 12171564
    [Abstract] [Full Text] [Related]

  • 4. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions.
    Dagogo-Jack S, Santiago JV.
    Arch Intern Med; 1997 Sep 08; 157(16):1802-17. PubMed ID: 9290539
    [Abstract] [Full Text] [Related]

  • 5. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Sep 08; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 6. Effects of current therapeutic interventions on insulin resistance.
    Kobayashi M.
    Diabetes Obes Metab; 1999 May 08; 1 Suppl 1():S32-40. PubMed ID: 11220286
    [Abstract] [Full Text] [Related]

  • 7. Protein tyrosine phosphatase 1B inhibitors as antidiabetic agents - A brief review.
    Verma M, Gupta SJ, Chaudhary A, Garg VK.
    Bioorg Chem; 2017 Feb 08; 70():267-283. PubMed ID: 28043717
    [Abstract] [Full Text] [Related]

  • 8. Interdependence of hepatic lipid and glucose metabolism: novel pharmacological targets for diabetes.
    Lind P.
    Curr Opin Investig Drugs; 2004 Apr 08; 5(4):395-401. PubMed ID: 15134280
    [Abstract] [Full Text] [Related]

  • 9. [Management of blood glucose--target of the management and its practice].
    Ishibashi S.
    Nihon Rinsho; 2006 Nov 08; 64(11):2089-94. PubMed ID: 17087301
    [Abstract] [Full Text] [Related]

  • 10. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH, van Haeften TW.
    Drugs; 1995 Aug 08; 50(2):263-88. PubMed ID: 8521759
    [Abstract] [Full Text] [Related]

  • 11. Sulfonyl group-containing compounds in the design of potential drugs for the treatment of diabetes and its complications.
    Chen X, Hussain S, Parveen S, Zhang S, Yang Y, Zhu C.
    Curr Med Chem; 2012 Aug 08; 19(21):3578-604. PubMed ID: 22664250
    [Abstract] [Full Text] [Related]

  • 12. Newly approved and promising antidiabetic agents.
    Combettes M, Kargar C.
    Therapie; 2007 Aug 08; 62(4):293-310. PubMed ID: 17983555
    [Abstract] [Full Text] [Related]

  • 13. New drug targets for type 2 diabetes and the metabolic syndrome.
    Moller DE.
    Nature; 2001 Dec 13; 414(6865):821-7. PubMed ID: 11742415
    [Abstract] [Full Text] [Related]

  • 14. Multiple drug targets in the management of type 2 diabetes.
    Moneva MH, Dagogo-Jack S.
    Curr Drug Targets; 2002 Jun 13; 3(3):203-21. PubMed ID: 12041735
    [Abstract] [Full Text] [Related]

  • 15. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.
    Fisman EZ, Motro M, Tenenbaum A.
    Adv Cardiol; 2008 Jun 13; 45():154-170. PubMed ID: 18230961
    [Abstract] [Full Text] [Related]

  • 16. Novel strategies for the pharmacological management of type 2 diabetes.
    Nourparvar A, Bulotta A, Di Mario U, Perfetti R.
    Trends Pharmacol Sci; 2004 Feb 13; 25(2):86-91. PubMed ID: 15102494
    [Abstract] [Full Text] [Related]

  • 17. Targeted glycemic control in type 2 diabetes.
    Skyler JS.
    J Fla Med Assoc; 1998 Aug 13; 85(2):7-15. PubMed ID: 9782713
    [No Abstract] [Full Text] [Related]

  • 18. Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus.
    Thareja S, Aggarwal S, Bhardwaj TR, Kumar M.
    Med Res Rev; 2012 May 13; 32(3):459-517. PubMed ID: 20814956
    [Abstract] [Full Text] [Related]

  • 19. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun 13; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 20. Treatment of non-insulin-dependent diabetes mellitus.
    Patel M, Rybczynski PJ.
    Expert Opin Investig Drugs; 2003 Apr 13; 12(4):623-33. PubMed ID: 12665417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.